MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan - Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues - NeurentMedical.com / Frost.com
Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2018/11/13 - Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues - NeurentMedical.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a non-surgical, minimally invasive device that uses radio frequency (RF) to modulate a nerve group to offer relief from nasal obstruction and rhinorrhea. With the total annual avoidable expenditure on the European allergy market, not limited to rhinitis, amounting between $50 billion and $150 billion, even back in 2014, Neurent Medical's out-patient device can help customers achieve significant savings by using RF in a highly targeted manner.

The current clinical gold standard approaches to treating chronic ear, nose, and throat infections range from avoiding various environmental triggers, which provides only temporary relief, to invasive surgery, which often requires lengthy recovery periods. Medications such as antihistamines, decongestants, and topical or systemic corticosteroids have limited patient and physician acceptance because of side effects, such as drowsiness, bleeding, drying, and crusting. In more severe cases, surface cautery of enlarged turbinates is performed as an out-patient procedure; however, side effects include edema and crusting in the nose that can last three weeks or longer. In such a scenario, Neurent Medical's single-use device presents exceptional value as it can be used in office settings, and patients can resume normal activity almost immediately after implantation.

"Neurent Medical has based its rhinitis device on its extensive research on neuronal activity in the nasal cavity and the cellular makeup of the nasal mucosa. These guiding principles have enabled the product to stand out as a low-powered RF treatment that targets the autonomic supply to the nasal turbinates, positively impacting both allergic and non-allergic rhinitis," said Arjunvasun, Industry Analyst at Frost & Sullivan. "The device uses a microelectrode array that is designed to deliver targeted energy to interrupt the autonomic function within mucosal structures of the nasal cavities to reverse inflammatory cascade. The device incorporates an intelligent RF generator to maximize the energy delivery to the intended target, while minimizing collateral damage to the sub-mucosal tissues."

Additionally, the device offers substantial cost savings by eliminating patients' dependence on pharmacotherapies and by requiring only a single out-patient procedure.

"Although the application of RF to treat rhinitis has been evaluated through clinical studies, Neurent Medical has pioneered its application in treating inflammation caused by rhinitis," noted Arjunvasun. "Research conducted at the National University of Ireland, Galway supports the claim that Neurent Medical’s solution is truly a game-changing technology for allergy patients worldwide."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognises the product’s value-added features/benefits and the increased return on investment (ROI) it provides to customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Neurent Medical

Neurent Medical Ltd (neurentmedical.com) is a privately held, venture backed, Galway (Ireland) based medical device company in the Ear, Nose and Throat market. The company designs and develops products for treating inflammatory diseases of the nasal cavities. The initial product offering reduces the primary symptoms of rhinitis, congestion and rhinorrhoea.

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Claudia Toscano - Frost.com 
210-477-8417 claudia.toscano[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)